US Bancorp DE Reduces Stock Position in Haleon plc (NYSE:HLN)

US Bancorp DE trimmed its holdings in Haleon plc (NYSE:HLN) by 3.0% during the fourth quarter, HoldingsChannel.com reports. The firm owned 734,815 shares of the company’s stock after selling 22,654 shares during the period. US Bancorp DE’s holdings in Haleon were worth $7,010,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in HLN. Addison Advisors LLC grew its stake in Haleon by 28.7% in the fourth quarter. Addison Advisors LLC now owns 4,954 shares of the company’s stock worth $47,000 after purchasing an additional 1,106 shares in the last quarter. Synovus Financial Corp lifted its holdings in Haleon by 0.8% during the 3rd quarter. Synovus Financial Corp now owns 148,834 shares of the company’s stock worth $1,575,000 after buying an additional 1,216 shares during the last quarter. Greenleaf Trust grew its position in shares of Haleon by 8.4% in the 4th quarter. Greenleaf Trust now owns 17,225 shares of the company’s stock worth $164,000 after acquiring an additional 1,333 shares in the last quarter. Baron Wealth Management LLC increased its holdings in shares of Haleon by 4.3% in the 4th quarter. Baron Wealth Management LLC now owns 33,632 shares of the company’s stock valued at $321,000 after acquiring an additional 1,381 shares during the last quarter. Finally, Peapack Gladstone Financial Corp raised its position in shares of Haleon by 3.2% during the 3rd quarter. Peapack Gladstone Financial Corp now owns 44,844 shares of the company’s stock valued at $474,000 after acquiring an additional 1,390 shares in the last quarter. 6.67% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have commented on HLN shares. Sanford C. Bernstein downgraded shares of Haleon from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 8th. Morgan Stanley lowered shares of Haleon from an “overweight” rating to an “equal weight” rating in a report on Friday, January 10th. Three investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $10.95.

Haleon Trading Up 0.9 %

Shares of NYSE HLN opened at $10.68 on Wednesday. Haleon plc has a 12-month low of $7.89 and a 12-month high of $10.80. The company has a market cap of $48.33 billion, a price-to-earnings ratio of 31.40, a price-to-earnings-growth ratio of 2.82 and a beta of 0.28. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. The stock’s 50 day simple moving average is $9.61 and its 200 day simple moving average is $9.84.

Haleon (NYSE:HLN) last posted its earnings results on Thursday, February 27th. The company reported $0.05 earnings per share (EPS) for the quarter. The company had revenue of $3.54 billion for the quarter, compared to analysts’ expectations of $3.38 billion. Haleon had a return on equity of 14.76% and a net margin of 10.85%. Equities research analysts expect that Haleon plc will post 0.43 EPS for the current year.

Haleon Increases Dividend

The company also recently announced a — dividend, which will be paid on Thursday, June 5th. Shareholders of record on Friday, April 25th will be paid a dividend of $0.1166 per share. This represents a yield of 1.6%. This is a positive change from Haleon’s previous — dividend of $0.05. The ex-dividend date is Friday, April 25th. Haleon’s payout ratio is presently 58.97%.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.